Inactive Instrument

iQX Limited Stock

IQX

AU000000IQX4

IQX Limited is an Australia-based investment funds management company specializing in the bioscience sector. The Company operates through two operating segments, financial services and office and shared services. The Company is engaged in investment activities and exploring investment opportunities primarily in Australian biotech and life science companies and other registered intellectual property. It is also engaged in underwriting primary and secondary capital raisings, and managing discretionary accounts. The Company's subsidiaries include iQX Capital Pty Ltd, iQX Investment Services Pty Ltd, Life Science Holdings Pty Ltd, iQ Capital Partners (No.1) Pty Ltd, iQ Series 8 Life Science (Global) LP, Neutron Investment Group Pty Ltd, Life Science Ventures (No.1) Pty Ltd, Prosoma Therapeutics (No.1) Pty Ltd, Prosoma Therapeutics (No.2) Pty Ltd, Prosoma Therapeutics (No.3) Pty Ltd, Prosoma Therapeutics (No.4) Pty Ltd, and Prosoma Therapeutics (No.5) Pty Ltd.

Employees

Sector

More about the company

21-09-09	IQX Limited Reports Earnings Results for the Full Year Ended June 30, 2021	CI
21-03-09	Iqx Limited Reports Earnings Results for the Half Year Ended December 31, 2020	CI
20-09-11	Iqx Limited Reports Earnings Results for the Full Year Ended June 30, 2020	CI
20-03-15	Iqx Limited Reports Earnings Results for the Half Year Ended December 31, 2019	CI
19-09-16	Iqx Limited Reports Earnings Results for the Full Year Ended June 30, 2019	CI
19-03-18	IQX Limited Reports Consolidated Earnings Results for the Half Year Ended December 31, 2018	CI
19-01-14	IQX Limited announced that it has received AUD 1.244243 million in funding	CI
18-09-29	IQX Limited Reports Audited Consolidated Earnings Results for the Year Ended June 30, 2018	CI
18-09-14	IQX Limited Reports Unaudited Consolidated Earnings Results for the Year Ended June 30, 2018	CI
18-03-16	IQX Limited Reports Consolidated Earnings Results for the Half Year Ended December 31, 2017	CI
17-10-19	IQX Limited Reports Audited Consolidated Earnings Results for the Year Ended June 30, 2017	CI
17-03-16	IQX Limited Reports Consolidated Earnings Results for the Half Year Ended December 31, 2016	CI
16-01-07	1,600,000 shares of IQX Limited's Ordinary Shares are subject to a Lock-Up Agreement Ending on 8-JAN-2016.	CI

22-08-15	IQX : Continued Suspension - Non-payment of Annual Listing Fee 2022-2023	PU
22-08-05	IQX : Execution Of Deed Of Company Arrangement	PU
22-08-01	IQX : Outcome Of Creditors' Meeting	PU
22-03-16	IQX : Continued Suspension - Failure to lodge Half Yearly Financial Statements- 31 December 2021	PU
22-03-15	IQX : The phone number for the Voluntary Administrator was incorrect and nothing else has changed.	PU

Manager	Title	Age	Since
George Syrmalis CEO	Chief Executive Officer	62	2014-10-31
Kosmas Dimitriou SEC	Corporate Secretary	46	2021-12-12

Director	Title	Age	Since
Peter Buchanan Simpson BRD	Director/Board Member	73	2013-08-13
George Syrmalis BRD	Director/Board Member	62	2014-10-31
Kosmas Dimitriou CHM	Chairman	46	2012-10-31

iQX Limited Stock

Stocks

IQX

AU000000IQX4

Latest news : iQX Limited

Press Releases: iQX Limited

Quotes and Performance

Managers and Directors: iQX Limited

Company Profile